SGRY
Surgery Partners·NASDAQ
--
--(--)
--
--(--)
SGRY fundamentals
Surgery Partners (SGRY) released its earnings on Mar 2, 2026: revenue was 885.00M (YoY +2.38%), beat estimates; EPS was 0.12 (YoY -72.73%), missed estimates.
Revenue / YoY
885.00M
+2.38%
EPS / YoY
0.12
-72.73%
Report date
Mar 2, 2026
SGRY Earnings Call Summary for Q4,2025
- Revenue Growth: 2025 net revenue $3.3 billion (+6.2% YoY), but Q4 EBITDA miss due to Medicare mix shift and 3 underperforming surgical hospitals.
- 2026 Outlook: Revenue $3.35-$3.45 billion, EBITDA $530+ million. Includes $8M state tax and $4M tariff headwinds, plus $9M M&A contribution.
- Strategic Moves: $200M share buyback authorized; 8 new ASCs opened in 2025, 5 under construction. Baylor JV example of portfolio optimization.
- Growth Drivers: Orthopedics (15% Q4 total joint growth), robotics (74 surgical robots), and vascular expansion. 2026 focus on physician recruitment, cost containment, and de novo development.
EPS
Actual | -0.34 | -0.48 | -0.53 | 0.09 | -0.3 | -0.0016 | -0.05 | 0.23 | -0.09 | -0.03 | -0.02 | 0.27 | 0.08 | 0.28 | 0.19 | 0.44 | 0.1 | 0.21 | 0.19 | 0.44 | 0.04 | 0.17 | 0.13 | 0.12 | |||||||||||
Forecast | -0.4458 | -0.6913 | -0.3785 | 0.0164 | -0.3713 | -0.1568 | -0.0593 | 0.1938 | -0.0709 | -0.0194 | 0.0457 | 0.2032 | 0.0037 | 0.0809 | 0.1431 | 0.3786 | 0.0715 | 0.1995 | 0.2515 | 0.3759 | 0.0661 | 0.1765 | 0.2029 | 0.3042 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +23.73% | +30.57% | -40.03% | +448.78% | +19.20% | +98.98% | +15.68% | +18.68% | -26.94% | -54.64% | -143.76% | +32.87% | +2062.16% | +246.11% | +32.77% | +16.22% | +39.86% | +5.26% | -24.45% | +17.05% | -39.49% | -3.68% | -35.93% | -60.55% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 441.00M | 374.70M | 496.10M | 548.30M | 512.40M | 543.30M | 559.20M | 610.20M | 596.20M | 615.40M | 620.60M | 707.10M | 666.20M | 667.60M | 674.10M | 735.40M | 717.40M | 762.10M | 770.40M | 864.40M | 776.00M | 826.20M | 821.50M | 885.00M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 405.09M | 302.26M | 462.15M | 548.64M | 494.74M | 533.43M | 543.03M | 624.38M | 576.58M | 623.90M | 633.99M | 688.06M | 656.74M | 669.43M | 671.99M | 741.45M | 698.73M | 735.94M | 768.99M | 827.90M | 777.34M | 818.43M | 820.03M | 866.82M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +8.86% | +23.97% | +7.35% | -0.06% | +3.57% | +1.85% | +2.98% | -2.27% | +3.40% | -1.36% | -2.11% | +2.77% | +1.44% | -0.27% | +0.31% | -0.82% | +2.67% | +3.56% | +0.18% | +4.41% | -0.17% | +0.95% | +0.18% | +2.10% |
Earnings Call
You can ask Aime
What guidance did Surgery Partners's management provide for the next earnings period?What were the key takeaways from Surgery Partners’s earnings call?Did Surgery Partners beat or miss consensus estimates last quarter?What is Surgery Partners's gross profit margin?What is the market's earnings forecast for Surgery Partners next quarter?What is Surgery Partners's latest dividend and current dividend yield?What were the key takeaways from Surgery Partners's earnings call?What factors drove the changes in Surgery Partners's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
